VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
CYHCommunity Health Systems, Inc.
$3.28$462M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksCYHFinancials

Community Health Systems, Inc. (CYH) Financials

27Y historyFree accessUpdated daily

Revenue growth remains stagnant, fluctuating between -4.9% and 2.8% over the last ten quarters, while gross margins exhibit extreme volatility, swinging from -134.6% in 2025Q4 to 96.6% in 2026Q1.

CYH Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99
Sales/Revenue21.48B12.48B12.63B12.49B12.21B12.37B11.79B13.21B14.15B15.35B18.44B19.44B18.64B13B13.03B11.91B11.4B12.11B10.84B7.13B4.37B3.74B3.33B2.83B2.2B1.69B1.34B1.08B
Revenue Growth %69.78%-1.18%1.15%2.28%-1.27%4.91%-10.76%-6.68%-7.8%-16.73%-5.14%4.28%43.4%-0.24%9.43%4.46%-5.86%11.69%52.09%63.27%16.78%12.17%17.57%28.82%29.92%26.63%23.85%-
Cost of Goods Sold9.96B11.4B7.36B7.41B7.3B7.28B7.37B8.1B8.74B10.05B11.63B12.04B11.48B8.08B7.95B1.83B1.77B6.53B5.85B3.84B2.25B1.93B1.74B912.8M1.38B323.81M259.47M209.08M
COGS % of Revenue-91.33%58.29%59.31%59.82%58.89%62.55%61.3%61.74%65.45%63.1%61.94%61.59%62.18%60.98%15.4%15.54%53.91%53.92%53.87%51.58%51.75%52.2%32.2%62.83%19.12%19.4%19.36%
Gross Profit11.53B1.08B5.27B5.08B4.91B5.08B4.42B5.11B5.42B5.3B6.8B7.4B7.16B4.74B4.89B10.07B9.63B5.58B4.99B3.29B2.11B1.8B1.59B1.92B817.99M1.37B1.08B870.87M
Gross Margin %53.66%8.67%41.71%40.69%40.18%41.11%37.45%38.7%38.26%34.55%36.9%38.06%38.41%36.44%37.52%84.6%84.46%46.09%46.08%46.13%48.42%48.25%47.8%67.8%37.17%80.88%80.6%80.64%
Gross Profit Growth %--79.47%3.7%3.59%-3.5%15.15%-13.63%-5.61%2.09%-22.02%-8.04%3.34%51.13%-3.09%-51.47%4.63%72.53%11.72%51.91%55.52%17.2%13.22%-17.1%134.95%-40.28%27.07%23.79%-
Operating Expenses20.08B11B4.73B4.13B4.08B3.68B3.29B4.46B5.21B7.18B7.66B6.06B5.82B3.82B3.75B9B8.51B4.51B9.86B2.8B1.73B1.4B1.25B1.63B1.96B1.18B922.91M765.61M
OpEx % of Revenue-88.08%37.42%33.03%33.45%29.77%27.9%33.78%36.79%46.79%41.56%31.18%31.22%29.39%28.74%75.6%74.68%37.26%90.93%39.31%39.71%37.4%37.64%57.54%89.02%69.72%69%70.89%
Selling, General & Admin10.62B0299M319M317M308M327M321M337M394M450M457M434M279M264M5.83B5.5B247.13M4.56B2.49B1.54B1.23B1.1B1.49B1.84B1.06B825.29M683.96M
SG&A % of Revenue--2.37%2.55%2.6%2.49%2.77%2.43%2.38%2.57%2.44%2.35%2.33%2.15%2.03%48.99%48.21%2.04%42.03%34.88%35.32%32.92%32.89%52.4%83.55%62.65%61.7%63.33%
Research & Development00080M85M108M0000000000000000000000
R&D % of Revenue---0.64%0.7%0.87%----------------------
Other Operating Expenses2M11B4.43B3.73B3.68B3.27B2.96B4.14B4.87B6.79B7.21B5.6B5.39B3.54B04.89B4.6B4.26B1.71B316.21M191.57M167.67M158.26M145.75M120.45M119.67M97.62M81.65M
Operating Income-8.55B-9.91B542M957M821M1.4B1.13B650M208M-1.88B-860M1.34B1.34B917M1.24B1.13B1.11B1.07B983.57M485.69M380.46M405.53M338.87M290.77M241.51M189.04M155.11M105.25M
Operating Margin %-39.82%-79.42%4.29%7.66%6.72%11.34%9.55%4.92%1.47%-12.23%-4.66%6.88%7.18%7.06%9.49%9.53%9.78%8.83%9.07%6.81%8.71%10.85%10.17%10.26%10.98%11.16%11.6%9.75%
Operating Income Growth %--1929.34%-43.36%16.57%-41.44%24.51%73.23%212.5%111.08%-118.37%-164.32%-0.15%46.02%-25.81%8.95%1.75%4.33%8.65%102.51%27.66%-6.18%19.67%16.54%20.4%27.75%21.88%47.37%-
EBITDA-7.82B-9.49B948M1.38B1.27B1.83B1.56B1.14B768M-1.2B39M2.3B2.19B1.55B1.95B1.79B1.72B1.64B1.49B818.26M569.23M571.7M497.25M434.54M359.73M308.71M252.74M186.91M
EBITDA Margin %-36.4%-76%7.5%11.06%10.4%14.83%13.24%8.61%5.43%-7.78%0.21%11.83%11.75%11.92%14.97%15.05%15.13%13.51%13.75%11.48%13.04%15.29%14.92%15.33%16.35%18.23%18.9%17.31%
EBITDA Growth %-889.2%-1100.95%-31.4%8.82%-30.75%17.49%37.29%48.05%164.27%-3164.1%-98.3%4.93%41.45%-20.56%8.81%3.91%5.48%9.73%82.13%43.75%-0.43%14.97%14.43%20.8%16.53%22.15%35.22%-
D&A (Non-Cash Add-back)734M426M406M425M449M432M435M487M560M683M899M962M852M632M714M657.66M609.84M566.54M506.69M332.58M188.77M166.16M158.38M143.77M118.22M119.67M97.62M81.65M
EBIT4.23B1.59B843M870M719M1.28B573M902M892M216M1.08B1.42B1.64B1.05B1.24B1.12B1.17B1.1B1.04B477.54M385.06M398.46M342.47M293.81M242.47M189.04M155.11M105.25M
Net Interest Income-864M-870M-860M-830M-858M-885M-1.03B-1.04B-976M-931M-962M-973M-972M-613M-621M-644.41M-647.59M-643.61M-652.47M-362.06M00000000
Interest Income003M2M0000011M0002.98M04.65M1.76M3.56M7.06M8.18M00000000
Interest Expense864M870M863M832M858M885M1.03B1.04B976M942M962M973M972M615.15M622.93M649.06M653.68M648.96M658.98M364.53M102.3M94.61M77.86M71.09M62.86M94.55M00
Other Income/Expense8.33B10.64B-825M-750M-472M-903M-704M0-923M-955M-855M-926M-997M-611.14M-706.35M-660.94M-606.49M-622.53M-607.34M-378.39M-104.1M-94.61M-72.44M-71.09M-62.86M-94.55M-127.37M-116.49M
Pretax Income-223M724M-283M207M349M499M422M-430M-715M-2.83B-1.72B411M342M305.86M503.77M473.55M508.43M446.13M336.14M102.9M278.16M310.92M260.22M219.68M178.65M94.5M27.74M-11.24M
Pretax Margin %-1.04%5.8%-2.24%1.66%2.86%4.03%3.58%-3.26%-5.05%-18.45%-9.3%2.11%1.83%2.35%3.87%3.98%4.46%3.68%3.1%1.44%6.37%8.32%7.81%7.75%8.12%5.58%2.07%-1.04%
Income Tax108M48M79M191M170M131M-185M160M-11M-449M-104M116M82M88.59M157.5M137.65M159.99M141.32M129.48M43M106.68M120.78M102M88.21M73.39M45.94M18.17M5.55M
Effective Tax Rate %-48.43%6.63%-27.92%92.27%48.71%26.25%-43.84%-37.21%1.54%15.85%6.06%28.22%23.98%28.97%31.26%29.07%31.47%31.68%38.52%41.79%38.35%38.85%39.2%40.15%41.08%48.62%65.51%-49.42%
Net Income-88M509M-516M-133M46M230M511M-590M-788M-2.46B-1.72B158M92M141.2M265.64M201.95M279.98M243.15M218.3M30.29M168.26M167.54M151.43M131.47M99.98M44.74M9.57M-16.79M
Net Margin %-0.41%4.08%-4.08%-1.06%0.38%1.86%4.33%-4.47%-5.57%-16.02%-9.33%0.81%0.49%1.09%2.04%1.7%2.46%2.01%2.01%0.43%3.85%4.48%4.54%4.64%4.54%2.64%0.72%-1.55%
Net Income Growth %81.93%198.64%-287.97%-389.13%-80%-54.99%186.61%25.13%67.95%-42.88%-1189.24%71.74%-34.85%-46.84%31.54%-27.87%15.15%11.38%620.74%-82%0.43%10.64%15.18%31.49%123.46%367.58%157%-
Net Income (Continuing)-331M676M-362M16M179M368M607M-590M-704M-2.38B-1.61B295M260M242M358M335.89M355.21M304.81M246.76M75.89M174.27M193.24M162.36M135.42M100.8M48.55M9.57M-16.79M
Discontinued Operations000000000000000001.01M-13.03M-8.46M3.42M-4.87M-916K00000
Minority Interest260M557M597M568M633M562M571M579M576M602M667M657M611M422.05M432.98M463.09M448.38M64.78M325.2M366.13M00000000
EPS (Diluted)-0.653.77-3.90-1.020.351.764.38-5.19-6.99-22.00-15.541.370.821.512.962.233.012.662.320.321.751.791.511.301.000.500.14-0.31
EPS Growth %82.32%196.67%-282.35%-391.43%-80.11%-59.82%184.39%25.75%68.23%-41.57%-1234.31%67.07%-45.7%-48.99%32.74%-25.91%13.16%14.66%625%-81.71%-2.23%18.54%16.15%30%100%257.14%145.16%-
EPS (Basic)-3.80-3.90-1.020.361.824.42-5.19-6.99-22.00-15.551.380.821.512.982.243.052.682.340.321.771.891.581.341.020.510.14-0.31
Diluted Shares Outstanding135M135M132.1M130.45M130.06M130.6M116.54M113.74M112.73M111.77M110.73M115M113M93.81M89.81M90.67M92.95M91.52M94.29M94.64M96.23M98.58M100.29M101.13M108.38M90.25M69.19M54.55M
Basic Shares Outstanding134M134M132.1M130.39M128.81M126.75M115.49M113.74M112.73M111.77M110.71M114M112M92.63M89.24M89.97M91.72M90.61M93.37M93.52M94.98M88.6M95.64M98.39M98.42M88.38M67.61M54.55M
Dividend Payout Ratio--------------8.48%-------0.82%-----

Key Metrics

Growth RegimeMixed
ProfitabilityStrained
Balance SheetVulnerable
Cash FlowMixed
Top Statement Risk

High leverage and refinancing

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Stagnant Revenue Amid Portfolio Rationalization

According to quarterly financial disclosures, CYH has struggled to generate meaningful top-line momentum, with revenue growth fluctuating between -4.9% and 2.8% over the last ten quarters, reflecting the ongoing impact of a persistent divestiture strategy that continues to shrink the company's overall operational footprint.

The lack of consistent organic growth suggests that the company's core hospital assets are failing to capture sufficient volume to offset the loss of revenue from sold facilities. Investors should monitor whether the remaining portfolio can achieve scale-driven efficiencies or if the current trajectory indicates a long-term decline in market relevance.

Volatile Margins Mask Operational Instability

As reported in recent income statements, gross margins have exhibited extreme volatility, swinging from a negative 134.6% in 2025Q4 to a high of 96.6% in 2026Q1, which suggests that accounting adjustments and non-recurring items are significantly distorting the underlying profitability of the company's core healthcare services.

This erratic margin profile makes it difficult to assess the true pricing power of the firm's rural and secondary market facilities. The wide variance implies that management is likely grappling with significant cost-of-goods-sold fluctuations, potentially linked to labor shortages or shifting reimbursement models that remain difficult to forecast.

Operating Leverage Obscured by Impairments

Based on the provided income statement data, the company's operating income has shown wild swings, including a massive negative $11.0 billion in 2025Q4, which indicates that non-cash impairment charges are likely overwhelming the operational performance of the underlying hospital network and masking true overhead efficiency.

The inability to maintain a stable operating margin suggests that the company's high fixed-cost structure is a significant liability during periods of volume contraction. Analysts should be wary of interpreting these figures as representative of day-to-day operational health, as the volatility appears driven by balance sheet cleanup rather than service delivery.

Earnings Quality Compromised by Volatility

Analysis of the reported figures reveals that net income is frequently disconnected from operating performance, with the company swinging between significant losses and occasional profits, such as the $282 million net income reported in 2025Q2, suggesting that non-operating items are the primary drivers of bottom-line results.

The reliance on non-operating income to achieve positive net results warrants further investigation into the sustainability of these earnings. Investors should prioritize cash flow from operations over reported net income, as the latter appears heavily influenced by accounting maneuvers that do not reflect the company's core cash-generating capacity.

Structural Risks to Long-Term Viability

While management emphasizes a strategy of divesting underperforming assets to reduce debt, the persistent contraction of the hospital portfolio, as evidenced by the recent income statement trends, suggests a potential death spiral where the loss of scale leads to higher relative overhead and diminished competitive positioning.

Short-sellers may focus on the company's inability to achieve consistent organic growth despite years of restructuring efforts. The risk remains that the remaining assets are insufficient to support the company's debt load, potentially necessitating further asset sales that could leave the firm with only its most distressed and least profitable facilities.

CYH — Frequently Asked Questions

Quick answers to the most common questions about buying CYH stock.

What was Community Health Systems, Inc.'s (CYH) revenue in 2025?

For fiscal year 2025, Community Health Systems, Inc. (CYH) reported total revenue of $12.48B. This represents a 1056.1% increase compared to $1.08B in 1999.

Is Community Health Systems, Inc. (CYH) profitable?

Community Health Systems, Inc. (CYH) is profitable, generating $509.0M in net income for the fiscal year ending 2025 with a net profit margin of 4.1%.

What is Community Health Systems, Inc.'s operating profit margin?

Community Health Systems, Inc. (CYH) reported an operating income of $-9915.0M, resulting in an operating profit margin of -79.4%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Community Health Systems, Inc.'s gross profit and gross margin?

Community Health Systems, Inc. (CYH) generated $1.08B in gross profit for the year, representing a gross profit margin of 8.7%. This demonstrates the company's core pricing power and production efficiency.